Oncolytics Biotech shares surge 11.11% intraday after Lake Street Capital initiates Buy rating and coverage.

think> Okay, let's tackle this query step by step. The user wants me to act as a financial analyst explaining Oncolytics Biotech's stock price movement based on recent news. The stock went up 11.11% intraday. First, I need to check the provided news events. The input has two main sections under "Recent News Events," each with multiple articles. The first section is under a title from MarketBeat dated August 18, 2025, but the content includes various news from August 8 to August 17, 2025. The second section is from another MarketBeat entry on September 1, 2025, with news from May 2023 to September 2023. Wait, the stock movement is in 2025 (given the trading period is intraday), but some of the news is from 2023. That might be a mix-up in the input. The user might have included historical data by mistake. Now, I need to focus on the most recent news relevant to the stock's movement. The stock price increased intraday on August 18, 2025. The relevant news from the first section includes announcements from August 8-17, 2025. Let me look for positive events in that timeframe. Looking at the August 8, 2025 news: Oncolytics reported reduced losses in Q2 2025, which is positive. They also announced a voluntary delisting from the Toronto Stock Exchange, which could be seen as a strategic move. Additionally, they regained compliance with Nasdaq trading rules on July 22, 2025, which is a positive development. On July 29, they had a 3.8% stock price increase and announced plans to engage the FDA for a pancreatic cancer study. There's also a buy recommendation from Lake Street Capital on August 14, 2025. The key positive events seem to be the reduced Q2 losses, the FDA engagement for a potential trial, and the buy recommendation. The delisting might have some mixed signals, but if it's part of a strategy to focus on Nasdaq, that could be positive. The regain of Nasdaq compliance is also a positive as it avoids delisting issues. However, some news is from earlier in 2025, like the FDA engagement in July. The recent news on August 8 about reduced losses and delisting might be more directly related to the intraday price jump. Also, the buy recommendation from Lake Street on August 14 could have contributed to investor confidence. I need to check if these events align with the stock's upward movement. The stock surged 11.11% intraday, which is significant. The most recent relevant news before the price movement would be the Q2 financial results showing reduced losses and the FDA engagement for a pancreatic cancer trial. The buy recommendation from Lake Street on August 14 (a week before the price jump) might have set a positive tone. Wait, the stock movement is on August 18, so the news up to August 17 would be relevant. The Q2 results were announced on August 8, and the delisting on August 8. The regain of Nasdaq compliance was July 22, which is a few weeks prior. The FDA engagement was July 29. The Lake Street buy recommendation was August 14. So, the cumulative effect of these positive developments—reduced losses, strategic delisting, Nasdaq compliance, FDA engagement, and analyst upgrades—could have driven the stock up. However, the user's instruction says to identify the key news likely causing the move. The most immediate catalyst might be the Q2 results and the FDA engagement. The delisting might be seen as a strategic move to streamline operations, which could be positive. I need to ensure that the news events are from 2025 and not 2023. The second section has news from 2023, which is outdated and shouldn't be considered. The user might have mixed up the dates. The first section's news is from 2025, so that's relevant. Putting it all together, the concise explanation should mention the stock's 11.11% intraday gain, the trading session, and the key news: reduced Q2 losses, FDA engagement for a pancreatic cancer trial, and the buy recommendation from Lake Street. Also, the delisting from TSE as part of strategic focus. However, the delisting might be a neutral or mixed event, but if it's part of a strategy to focus on Nasdaq, it's positive. I need to check if all the mentioned news are from 2025 and relevant. The answer should be under 150 words, so.